Prophylaxis against Hepatitis B Recurrence Following Liver Transplantation in HBsAg( ) Patients: Hepatitis B Immune Globulin vs Lamivudine.
- Author:
Kwang Woong LEE
1
;
Jae Berm PARK
;
Jae Won JOH
;
Sung Joo KIM
;
Geon Do SONG
;
Seong Ho CHOI
;
Jin Seok HEO
;
Yong Il KIM
;
Byung Boong LEE
;
Jeong Han KIM
;
Suk Koo LEE
Author Information
1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
HBV recurrence;
Prophylaxis;
Liver transplantation;
Hepatitis B Immune globulin;
Lamivudine
- MeSH:
Antiviral Agents;
Fibrosis;
Follow-Up Studies;
Hepatitis B e Antigens;
Hepatitis B Surface Antigens;
Hepatitis B virus;
Hepatitis B*;
Hepatitis*;
Humans;
Korea;
Lamivudine*;
Liver Transplantation*;
Liver*;
Recurrence*
- From:Journal of the Korean Surgical Society
2001;60(6):640-643
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Thanks to hepatitis B immune globulin (HBIG) and antiviral agents such as Lamivudine , HBV cirrhosis is no longer a contraindication of liver transplantation. Actually it is frequent indication for liver transplantation in Korea. However, to date, the most effective HBV prophylaxis regimen has not been determined. The purpose of this study was to evaluate whether the regimen consisting of lamivudine and one-week HBIG for the hepatitis B virus (HBV) prophylaxis following liver transplantation is as effective as a long-term therapy of high dose HBIG. METHODS: From May 1996 to December 1999, 58 patients among a total of 80 cases of liver transplantation were hepatitis B surface antigen positive preoperatively. They were grouped into two protocol regimens, the HBIG group and the Lamivudine combination group, at random. 43 patients (19 patients in the HBIG group, twenty four patients in the Lamivudine combination group) who survived more than 90 days were included in this study. The recurrence was defined as the conversion of HBs-Ag from negative to positive. RESULTS: There was no statistical significance between the two groups in regards to age, sex or the preoperative positive rate of HBeAg. The mean follow-up duration was 27 months (range from 6-55). Of the 43 patients, 5 patients were converted to HBs-Ag positive in serum; two were in theHBIG group and three in the Lamivudine combination group. There was no statistical significance in HBV recurrence rate between the two groups (p=0.97). CONCLUSION: The combined therapy of lamivudine and one week HBIG has an effect equivalent to a long term therapy of high dose HBIG in HBV prophylaxis following liver transplantation.
